Lumito AB publishes Quarterly Report 1, 2024
Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]
Lumito AB publishes Quarterly Report 1, 2022
Lumito AB publishes Quarterly Report 1, 2022 Financial overview of the first quarter January 1 to March 31, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 430 (-6 825). Earnings per share before and after dilution amounted to SEK -0.04 (-0.08). Cash flow from operating […]
Lumito AB Quarterly Report (1 Jan to 31 March) 2021
Significant events during the first quarter of 2021 Lumito’s advisors in the field of pathology have had the opportunity to review the company’s UCNP immunostaining of invasive breast cancer with an antibody against HER2 (the target molecule) at a high image resolution. “The signals are uniquely sharp and clear, which gives the impression of staining […]
Lumito AB publishes Quarterly Report 1, 2021
Financial overview for the first quarter January 1st to March 31st, 2021 • Net sales amounted to SEK 0 (0) thousand • Profit after tax amounted to SEK -6,825 (-2,795) thousand. • Earnings per share before and after dilution amounted to SEK -0.08 (-0.04). • Cash flow from operating activities after changes in working capital […]
Quarterly report 1, 2020, Lumito AB (publ).
Financial overview of the first quarter, 1 January – 31 March 2020 Result after taxes amounted to kSEK -2,795 (-1,958). Basic and diluted earnings per share amounted to SEK -0.04 (-0.08). Cash flow from operating activities amounted to kSEK -2,793 (-1,958). Cash and cash equivalents amounted to kSEK 17,675 (8,079) on the balance sheet date. […]
